Mon, Sep 22, 2014, 12:52 AM EDT - U.S. Markets open in 8 hrs 38 mins

Recent

% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

  • lifetolive7 lifetolive7 Jul 31, 2013 7:47 AM Flag

    CYCC vs. SNSS

    SNSS priced over 15 X CYCC net of cash. Sapacitabine is oral, less toxic, doubled survival in refractory MDS (phase 2), being tested for Front -line AML (not refractory) . In SEAMLESS, SAP/DAC is demonstrating a 20% survival 2-3 years out ( SEAMLESS pilot arm) and is ahead of SNSS in combined therapy with Dacogen. In Refractory MDS (6X the size of AML market), SAP (AS A SINGLE AGENT) has doubled survival in a recent phase 2 study and garnered praise from MD Anderson investigators. SAP/SEL (solely owned CYCC drug combination) demonstrated strong activity in BRCA deficient solid tumors. SAP Has proven multi-year tolerability and maintenance potential.

    SNSS's drug causes nasty side effect off mucco-cystic oral lesions, is I V administration, being tested refractory AML, It is combined with Cytarabine (toxic chemo) which makes the drug combination less suitable for older patients, SNSS had to increase the size of their study at interim results to improve statistical benefit (implies only marginal benefit in results being demonstrated). Vosaroxin/CYT is not suitable as a long term (multi-year) maintenance regimen and now Vosaroxin mono therapy in AML appears to be off the table and their phase 2 results have been contradicted.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SNSS
7.34-0.06(-0.81%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.